Antecedent Biomarkers For AD: The Adult Children Study

$2,343,760P01FY2013AGNIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 39689057 Paper 39677464 Paper 39606367 Paper 39559880 Paper 39553251 Paper 39540665 Paper 39484251 Paper 39483923 Paper 39444005 Paper 39417134 Paper 39412405 Paper 39385241 Paper 39371140 Paper 39351959 Paper 39314357 Paper 39279994 Paper 39177169 Paper 39165480 Paper 39148846 Paper 39147830 Paper 39108475 Paper 39077866 Paper 39041391 Paper 39020361 Paper 39011113 Paper 39010871 Paper 39006421 Paper 38970402 Paper 38963256 Paper 38958563 Paper 38958117 Paper 38956096 Paper 38947090 Paper 38947044 Paper 38947004 Paper 38923730 Paper 38903124 Paper 38888066 Paper 38883718 Paper 38823362 Paper 38788065 Paper 38776513 Paper 38712163 Paper 38712073 Paper 38687811 Paper 38683905 Paper 38666355 Paper 38602816 Paper 38559166 Paper 38554257 Paper 38526701 Paper 38514824 Paper 38496633 Paper 38463962 Paper 38445545 Paper 38410465 Paper 38400792 Paper 38395947 Paper 38382645 Paper 38379519 Paper 38365585 Paper 38355735 Paper 38353984 Paper 38315956 Paper 38282413 Paper 38276892 Paper 38260384 Paper 38234733 Paper 38224546 Paper 38224146 Paper 38198251 Paper 38191490 Paper 38189981 Paper 38189749 Paper 38150745 Paper 38111006 Paper 38110045 Paper 38089583 Paper 38086495 Paper 38086389 Paper 38043122 Paper 38038976 Paper 38020401 Paper 38018701 Paper 38014176 Paper 38014038 Paper 37994004 Paper 37986935 Paper 37985223 Paper 37984853 Paper 37972072 Paper 37969113 Paper 37955090 Paper 37888107 Paper 37886506 Paper 37855447 Paper 37843849 Paper 37816871 Paper 37808808 Paper 37808092

Abstract

DESCRIPTION (provided by applicant): The overarching aim of this application is to greatly expand knowledge about preclinical AD and specifically to characterize the chronology of biomarker changes, determine their path biological signatures (if any), and identify cognitively normal persons who are at very high risk for developing symptomatic AD. Successful treatment strategies will require biomarkers that can identify individuals at high risk for AD and at the earliest clinical stages in order to target them for clinical trials, disease- modifying therapies nd to monitor therapy success. The overall Specific Aims in this renewal application are to: 1. Follow the current participants in ACS and add new enrollees to maintain the sample size at ~300. 2. Obtain longitudinal data from the ACS participants at 2 year intervals with the following measures: a. Clinical and cognitive assessments (Clinical Core) b. Amyloid imaging with PET PIB (Project 1) c. Assays of amyloid-beta (A¿), tau, phosphorylated tau181 (p- tau181), and novel analytes in CSF and blood (Project 2, supported by the Biomarker Core) d. Attentional control battery and task-related functional MRI (fMRI) (Project 3) e. Structural MRI, resting state functional connectivity MRI (fcMRI), diffusion tensor imaging (DTI), and cerebral blood flow using arterial spin labeling (ASL) (Project 4) 3. Analyze associations among rates of change of all disease markers from all Cores and Projects (Data Management and Biostatistics Core).

View original record on NIH RePORTER →